uniQure to Participate in Multiple Upcoming Industry Conferences in May
May 03 2021 - 7:05AM
uniQure to Participate in Multiple Upcoming Industry Conferences in
May
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced its participation in the following upcoming
virtual investor and scientific conferences:
-
7th Annual Truist
Securities Life Sciences Summit, May 4 - 5, 2021
- Members of uniQure’s management
team will participate in virtual one-on-one investor meetings
throughout the day on Tuesday, May 4.
- American Society of Gene
and Cell Therapy (ASGCT) Virtual 2021, May 11 - 14, 2021
- uniQure will have a significant
presence at ASGCT with five data presentations, of which two are
oral presentations including:
- “Clinical Outcomes in Patients With
and Without Pre-existing Neutralizing Antibodies to the Vector:
6-Month Data from the Phase 3 HOPE-B Gene Therapy Trial of
Etranacogene Dezaparvovec” on Wednesday, May 12, 6:15 – 6:30 p.m.
ET.
- “First Proof-of-Concept of
miQURETM Based Gene Targeting in the Liver: Lipid Lowering and
Atherosclerosis Suppression by AAV-miQURETM-Mediated ANGPTL3
Targeting” on Thursday, May 13, 6:30 – 6:45 p.m. ET.
- 2021 RBC Capital Markets
Global Healthcare Conference, May 18 - 19, 2021
- Members of uniQure’s management
team will participate in virtual one-on-one investor meetings
throughout the day on Tuesday, May 18.
- A fireside chat with Matt Kapusta,
chief executive officer, will take place the same day from 9:10 to
9:35 a.m. ET. The live webcast of the fireside chat can be accessed
through the link displayed in the Investors & Newsroom section
of the uniQure website.
About uniQure uniQure is
delivering on the promise of gene therapy – single treatments with
potentially curative results. We are leveraging our modular and
validated technology platform to rapidly advance a pipeline of
proprietary gene therapies to treat patients with hemophilia B,
Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3
and other diseases. www.uniQure.com
uniQure Contacts:
FOR
INVESTORS: |
|
FOR
MEDIA: |
|
|
|
Maria E. Cantor |
Chiara Russo |
Tom Malone |
Direct: 339-970-7536 |
Direct: 617-306-9137 |
Direct: 339-970-7558 |
m.cantor@uniQure.com |
c.russo@uniQure.com |
t.malone@uniQure.com |
Uniqure NV (TG:UQ1)
Historical Stock Chart
From Jul 2024 to Aug 2024
Uniqure NV (TG:UQ1)
Historical Stock Chart
From Aug 2023 to Aug 2024